---

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.
20549FORM 10-Q(Mark One)[x]
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934For the quarterly period ended December 31, 2009OR[
] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from _______________to
_______________
Commission file number
______________PURE PHARMACEUTICALS CORPORATION(Exact name of
Registrant as Specified in Its Charter)

|NEVADA                                           | 45-0476087                       
|------------------------------------------------ | ---------------------------------
|(State or Other Jurisdiction of Incorporation or | (IRS Employer Identification No.)
|Organization)                                    |                                  
|                                                 |                                  
|                                                 |                                  
|P.O. BOX 55, 1594 STONE MILL PARK,               |                                  
|BELLONA, NY                                      | 14415                            
|(Address of Principal Executive Offices)         | (Zip Code)                       

(315) 849-2822(Registrants Telephone Number,
Including Area Code)

________________(Former Name, Former Address and Former Fiscal Year, if
Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.

Yes [x]    No [ ]

Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated filer. See
definition of accelerated filer and large accelerated filer in Rule 12b-2 of
the exchange Act. (Check One)

|Large Accelerated Filer [ ] | Accelerated Filer [ ] | Non-Accelerated Filer [
]
|--------------------------- | --------------------- | -------------------------

---

Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act).

Yes [x]   No [ ]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all
documents and reports required to be filed by Sections 12, 13 or 15(d) of the
Securities Exchange Act of 1934 subsequent to the distribution of securities
under a plan confirmed by a court.

Yes [ ]   No [ ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the
issuers classes of common stock, as of the latest practicable date.

*Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):

|Large accelerated filer [ ]                   | Accelerated filer [ ]        
|--------------------------------------------- | -----------------------------
|                                              |                              
|Non-accelerated filer [ ]                     | Smaller reporting company [x]
|(Do not check if a smaller reporting company)

---

PART 1FINANCIAL
INFORMATION

Item 1. Financial Statements.

PURE PHARMACEUTICAL CORPORATION(A Development
Stage Company)

****FINANCIAL
STATEMENTSDECEMBER 31, 2009

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|                               
|BALANCE SHEETS                 
|                               
|(Unaudited)                    

|                                                                                                                                                               |  |              |   |  |               |  
|-------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------ | - |  | ------------- | -
|                                                                                                                                                               |  | December 31, |   |  | September 30, |  
|                                                                                                                                                               |  | 2009         |   |  | 2009          |  
|                                                                                                                                                               |  | - $
      -  |   |  | - $
      -   |  
|                                                                                                                                                               |  |              |   |  |               |  
|ASSETS                                                                                                                                                         |  |              |   |  |               |  
|Current                                                                                                                                                        |  |              |   |  |               |  
|Cash                                                                                                                                                           |  | 6,510        |   |  | 8,573         |  
|                                                                                                                                                               |  | 6,510        |   |  | 8,573         |  
|                                                                                                                                                               |  |              |   |  |               |  
|LIABILITIES                                                                                                                                                    |  |              |   |  |               |  
|Current                                                                                                                                                        |  |              |   |  |               |  
|Accounts payable and accrued liabilities                                                                                                                       |  | 24,507       |   |  | 30,771        |  
|                                                                                                                                                               |  |              |   |  |               |  
|Long-term
      loans                                                                                                                                          |  | 43,431       |   |  | 59,314        |  
|                                                                                                                                                               |  | 67,938       |   |  | 90,085        |  
|                                                                                                                                                               |  |              |   |  |               |  
|STOCKHOLDERS DEFICIT                                                                                                                                          |  |              |   |  |               |  
|Common Stock(Note 2)                                                                                                                                           |  |              |   |  |               |  
|Authorized: 100,000,000 common shares
      with a par value of $0.001 Issued and Outstanding: 12,600,000
      common shares (September 30, 2009 12,600,000) |  | 12,600       |   |  | 12,600        |  
|Additional paid up capital                                                                                                                                     |  | 223,800      |   |  | 191,400       |  
|Accumulated other comprehensive income                                                                                                                         |  | 2,439        |   |  | 2,439         |  
|Deficit
      accumulated during the development stage                                                                                                         |  | (300,267     | ) |  | (287,951      | )
|                                                                                                                                                               |  | (61,428      | ) |  | (81,512       | )
|                                                                                                                                                               |  | 6,510        |   |  | 8,573         |  

 See Accompanying Notes 

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|STATEMENTS OF OPERATIONS       
|                               
|(Unaudited)                    

|                                                                                     |  |              |   |  |              |   |  |                |  
|------------------------------------------------------------------------------------ |  | ------------ | - |  | ------------ | - |  | -------------- | -
|                                                                                     |  |              |   |  |              |   |  | Cumulative     |  
|                                                                                     |  |              |   |  |              |   |  | from           |  
|                                                                                     |  |              |   |  |              |   |  | September 24,  |  
|                                                                                     |  | Three months |   |  | Three months |   |  | 2004           |  
|                                                                                     |  | ended        |   |  | ended        |   |  | (Inception) to |  
|                                                                                     |  | December 31, |   |  | December 31, |   |  | December 31,   |  
|                                                                                     |  | 2009         |   |  | 2008         |   |  | 2009           |  
|                                                                                     |  | -
      $ -  |   |  | -
      $ -  |   |  | -
      $ -    |  
|                                                                                     |  |              |   |  |              |   |  |                |  
|Revenue                                                                              |  | -            |   |  | 4,000        |   |  | 20,398         |  
|Cost of
      sales                                                                  |  | -            |   |  | -            |   |  | 9,670          |  
|                                                                                     |  | -            |   |  | 4,000        |   |  | 10,728         |  
|                                                                                     |  |              |   |  |              |   |  |                |  
|Expenses                                                                             |  |              |   |  |              |   |  |                |  
|Financing fees                                                                       |  | -            |   |  | -            |   |  | 5,600          |  
|General and administrative                                                           |  | 11,516       |   |  | 5,343        |   |  | 295,541        |  
|Interest on long-term loans                                                          |  | 800          |   |  | 800          |   |  | 4,724          |  
|Write-down of inventory                                                              |  | -            |   |  | -            |   |  | 5,130          |  
|Net loss                                                                             |  | (12,316      | ) |  | (2,143       | ) |  | (300,267       | )
|                                                                                     |  |              |   |  |              |   |  |                |  
|Loss per share
       basic and diluted                                             |  | (0.00        | ) |  | (0.00        | ) |  |                |  
|                                                                                     |  |              |   |  |              |   |  |                |  
|Weighted
      average number of common shares outstanding- basic
      and dilutive |  | 12,600,000   |   |  | 12,600,000   |   |  |                |  

 See Accompanying Notes 

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|                               
|STATEMENTS OF CASH FLOWS       
|                               
|(Unaudited)                    

|                                               |  |             |   |  |             |   |  |                    |  
|---------------------------------------------- |  | ----------- | - |  | ----------- | - |  | ------------------ | -
|                                               |  | Three       |   |  | Three       |   |  | Cumulative from    |  
|                                               |  | months      |   |  | months      |   |  | September 24, 2004 |  
|                                               |  | ended       |   |  | ended       |   |  | (Inception) to     |  
|                                               |  | December    |   |  | December    |   |  | December 31,       |  
|                                               |  | 31, 2009    |   |  | 31, 2008    |   |  | 2009               |  
|                                               |  | - $
      - |   |  | - $
      - |   |  | - $
      -        |  
|                                               |  |             |   |  |             |   |  |                    |  
|Cash Flows From Operating Activities           |  |             |   |  |             |   |  |                    |  
|Net loss                                       |  | (12,316     | ) |  | (2,143      | ) |  | (300,267           | )
|Non-cash items:                                |  |             |   |  |             |   |  |                    |  
|Accrued interest on long term loan             |  | 800         |   |  | 800         |   |  | 4,724              |  
|Donated capital                                |  | 2,400       |   |  | 2,400       |   |  | 50,400             |  
|Write down of inventory                        |  | -           |   |  | -           |   |  | 5,130              |  
|Change in non-cash working capital items:      |  |             |   |  |             |   |  |                    |  
|Inventory                                      |  | -           |   |  | -           |   |  | (5,130             | )
|Accounts payable
      and accrued liabilities |  | (6,264      | ) |  | (263        | ) |  | 54,507             |  
|Net cash used in operating activities          |  | 15,380      |   |  | 794         |   |  | (190,636           | )
|                                               |  |             |   |  |             |   |  |                    |  
|Cash Flows From Financing Activities           |  |             |   |  |             |   |  |                    |  
|Proceeds from (repayment of) long-term loans   |  | (16,683     | ) |  | -           |   |  | 38,707             |  
|Donated capital                                |  | 30,000      |   |  | -           |   |  | 50,000             |  
|Capital stock
      issued for cash            |  | -           |   |  | -           |   |  | 136,000            |  
|Net cash provided by financing activities      |  | (13,317     | ) |  | -           |   |  | 224,707            |  
|                                               |  |             |   |  |             |   |  |                    |  
|Effect of exchange rate changes                |  | -           |   |  | (29         | ) |  | 2,439              |  
|                                               |  |             |   |  |             |   |  |                    |  
|Increase (Decrease) In Cash                    |  | (2,063      | ) |  | (765        | ) |  | 6,510              |  
|                                               |  |             |   |  |             |   |  |                    |  
|Cash, beginning                                |  | 8,573       |   |  | 12,459      |   |  | -                  |  
|Cash,
      ending                             |  | 6,510       |   |  | 13,224      |   |  | 6,510              |  
|                                               |  |             |   |  |             |   |  |                    |  
|Supplementary Cash Flow Information:           |  |             |   |  |             |   |  |                    |  
|Cash paid for:                                 |  |             |   |  |             |   |  |                    |  
|Interest                                       |  | -           |   |  | -           |   |  | -                  |  
|Income taxes                                   |  | -           |   |  | -           |   |  | -                  |  

- See Accompanying Notes -

---

|PURE PHARMACEUTICAL CORPORATION 
|--------------------------------
|(A Development Stage Company)   
|                                
|NOTE TO THE FINANCIAL STATEMENTS
|                                
|DECEMBER 31, 2009               
|(Unaudited)                     

|1. | BASIS OF PRESENTATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
|-- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   | Unaudited Interim Consolidated Financial
      Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   | The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission.  They may not include all information and footnotes required by generally accepted accounting principles for complete financial statements.   However, except as disclosed herein, there has been no material changes in the information disclosed in the notes to the financial statements for the year ended September 30, 2009, included in the Company’s Form 10-K filed with the Securities and Exchange Commission. The unaudited interim financial statements should be read in conjunction with those financial statements included in the Form 10-K.  In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made.  Operating results for the three months ended December, 31, 2009 are not necessarily indicative of the results that may be expected for the year ending September 30, 2010.
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   | We evaluated events occurring between the end of our
      fiscal quarter December 31, 2009 and February 12, 2010 when the financial
      statements were issued.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|2. | COMMON STOCK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|   | During the three months ended December 31, 2009, the Company received $30,000 as the second installment of the $50,000 non-refundable required by the Letter of Intent (“LOI) entered into by the Company with 7167415 Canada Inc. on July 21, 2009.  The LOI expired on July 23, 2009 and a definitive agreement was not entered into.  Accordingly, the non-refundable deposit has been recorded as donated capital.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

---

|Item 2. | **Management's Discussion and
      Analysis of Financial Condition and Results of**
      **Operations.**
|------- | ----------------------------------------------------------------------------------------------------------

Forward Looking Statements

In addition to historical information, the following discussion
and other parts of this document may contain forward-looking statements. These
statements relate to future events or our future financial performance. In some
cases, you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," or "continue," the negative of such terms or other
comparable terminology. These statements are only predictions. The events
described in forward looking statements we make in this Form 10-Q may not occur.
Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. We caution you that these statements are
not guarantees of future performance or events and are subject to a number of
uncertainties risks and other influences, many of which are beyond our control
that may influence the accuracy of the statements and the projections upon which
the statements are based. Moreover, neither we nor any other person assume
responsibility for the accuracy and completeness of the forward-looking
statements. Except as may be required by law, we undertake no obligation to
publicly update any of the forward-looking statements after the date of this
report to conform such statements to actual results or to changes in our
expectations.

Actual results could differ materially from those anticipated
by such forward-looking statements. The following discussion should be read in
conjunction with the financial statements as well as other financial information
appearing elsewhere in this document. Readers are also urged to carefully review
and consider the various disclosures made by us which attempt to advise
interested parties of the factors which affect our business.

Our Business

The Company was formed in order to seek business opportunities
in the area of expertise of the Company's principal stockholder, Mr. Roger
Gordon, being biological and/or medical products for animal use. The Company
principally operated in the field of generic animal health and nutrition
products, specifically medicated feed additives (MFAs). MFAs are used
preventively and therapeutically in animal feed to prevent disease and foster
growth in livestock. In North America, 90% of all feed to animals contain MFAs,
but has been on the decrease in the last five years. Our intended customers
operate in the poultry, swine and cattle markets. The Company has historically
focused its efforts on generic MFAs, as they have come off patent, therefore
making them more economical to register with requisite regulators in the United
States and Canada, with a view to bringing the products to market.

The Company ceased to market an under licensed related-party
owned MFA, Oxytetracycline, and is continuing its discussions with third parties
in connection with a possible merger agreement or share exchange pursuant to
which control of the Company may be sold to such third parties. As market
dynamics have undergone significant systemic changes over the past four years
with the emergence of avian flu and the attendant fall in poultry consumption
worldwide, management realized the identification process for new MFAs cannot be
done with the limited resources of the Company. Furthermore, with the prices of
feed, particularly maize, at record high prices, out intended customers have
been hesitant to add to their expenses.

The Company's activities to date have been primarily
organizational in nature and as a result the Company must be considered to be in
its developmental stage. The Company relies solely on the efforts of its
management and director and has no employees, owns few business assets,
technology or real estate and since inception has been primarily involved in
developing and refining its business plan, preliminarily

---

identifying generic MFAs for registration, raising initial
capital, and looking for other potential shareholder maximizing corporate
actions.

Management previously determined to refocus, assess and
identify alternative business strategies due to prolonged high prices of maize
and other inputs and other general systemic economic conditions affecting the
business of the Company.

Recent Developments

The Company has booked no sales for this period and had
received $30,000 donated capital from an outside third party during the period.
As a result of the prolonged high prices of inputs and other general conditions
affecting the business of the Company, management determined, earlier in its
fiscal year, to refocus, assess and identify alternative business strategies. In
July 2008, the Company was quoted on the OTC Bulletin Board under the symbol
PPMA. The Company is continuing its discussions with third parties in
connection with a possible merger or share exchange pursuant to which control of
the Company may be sold to such third parties.

Results of Operations

Results of Operations for the Period ended December 31,
2009

The Company did not earn any revenues in the previous 3 months
ended December 31, 2009. We incurred operating expenses in the amount of
$12,316for the three months ended December 31, 2009. Our net loss for
the three months ended was $12,316 as compared to net loss of $2,143 for the
three months ended December 31, 2008. As at December 31, 2009 we had cash of
$6,510. The Companys losses stem from the payment of professional fees.

The Company ceased its sales and marketing of the Companys
Oxytetracyline as well as the process of the Company pursuing opportunities in
the generic MFAs areas. As stated in the prior quarter, the Company will not be
importing further Oxytetracyline from the Peoples Republic of China which is
idleling production until the overall economic situation improves; and our
factory suppliers have remained dormant and have not provided an ETA as to when
production would resume. Due to acute fluctuations in the price of key
ingredients; corn and soybeans; the ability for producers to manage price
pressure is severely challenged. Corn prices see-sawed and surged 3 to-5 fold in
the last 24 months to $750 USD per bushel mid 2008. Since its high, the price
has continued its volatility and as an example from June 1stto
December 31th2009 prices swung 22% in 30 days from $425 USD per
bushel to $350 USD per bushel. Farmers and buyers are taking a wait and see
approach and farmers in particular are not selling their crops and trying to
time the market. Management and analysts believe the competition for corn, once
viewed as a commodity and now viewed as a matter of national security for
countries, is here to stay. Though prices have dropped in the first six months
of 2009, the price is still double that of three years ago in January 2006, and
have trended upwards in the last half of 2009 The use of corn for the production
of ethanol and the agricultural polices of leading petroleum usage countries
continue to exert price and demand pressures on the market1. Also
confounding the problem is worldwide health concerns and reaction to animal
borne disease transmission to humans.

Due to the prolonged uncertainty and relative high historic
prices of inputs, this upward cycle has lasted for 3 years, and general economic
conditions which are effecting the business of the company; management has
determined to refocus, assess, and identify alternative business strategies.

|1http://www.financialpost.com/story.html?id=311350
|--------------------------------------------------

---

Liquidity and Capital Resources

Our cash reserves of $6,510as at December 31, 2009
($8,573 as at September 30, 2009) are not sufficient to meet our funding needs
beyond the next nine-month period. To this effect, the Company will need to seek
additional funding in the near future. We currently do not have a specific plan
for obtaining such funding, however, we anticipate that any additional funding
will be in the form of equity financing from the sale of our common stock and/or
loans (interest or convertible). We currently do not have any arrangements in
place for any future equity financing. We may also seek to obtain short-term
loans from our directors, although no such arrangements have as yet been made.
There can be no assurance that we will be able to raise sufficient funding from
the sale of our common stock or through director loans to meet our funding needs
after the next nine months.

The Independent Auditor's Report to our audited financial
statements for the period ended September 30, 2009 indicated that there are a
number of factors that raise substantial doubt about our ability to continue as
a going concern. Such factors identified in the report include that we need to
generate profitable operations and are in need of obtaining adequate financing.
For these and other related reasons our auditors believe that there is
substantial doubt that we will be able to continue as a going concern.

Comparison of Interim Financial Results

As at December 31, 2009, accounts payable balance is $24,507compared to $30,771as at September 30, 2009. Loan payable balance is
$43,431compared to $59,314as at September 30, 2009.

Sales have decreased year over year due to the increasing and
volatility prices of maize.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on the
small business issuer's financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that is material to investors.



|Item 3. | **Quantitative and Qualitative
      Disclosures About Market Risk.**
|------- | ---------------------------------------------------------------------

Not applicable.

Item 4.
    Controls and
Procedures.****

Evaluation of Disclosure Controls and Procedures. The
Company's Management under the supervision and with the participation of the
Principal Executive Officer and the Principal Financial Officer are responsible
for establishing and maintaining "disclosure controls and procedures" (as
defined in the Exchange Act) for the Company. Based on their evaluation of the
Company's disclosure controls and procedures as of December 31, 2009, the
Company's Management has concluded that the Company's disclosure controls and
procedures were effective to ensure that the information required to be
disclosed by the Company under the Exchange Act was recorded, processed,
summarized and reported within the time periods specified in the Exchange Act
and accumulated and communicated to the Company's Management, including the
Principal Executive Officer and the Principal Financial Officer, to allow timely
decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting.During the fiscal quarter ending December 31, 2009, there were no changes in
the Company's internal control over financial reporting during the period

---

covered by this report that have materially affected, or are
reasonably likely to materially affect, the Company's internal control over
financial reporting.

Limitations on the Effectiveness of Controls.A control
system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met.
Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that all control issues, if any, within
a company have been detected. The Company's disclosure controls and procedures
are designed to provide reasonable assurance of achieving their objectives, and
the Principal Executive Officer and the Principal Financial Officer have
concluded that these controls and procedures are effective at the "reasonable
assurance" level.



|Item 4T. | **Controls and
  Procedures.**
|-------- | ------------------------------

The Company's management is responsible for establishing and
maintaining adequate internal control over financial reporting. Our internal
control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted
accounting principles.

Our internal control over financial reporting includes those
policies and procedures that:

- Pertain to the maintenance of records that, in reasonable detail,
  accurately and fairly reflect the transactions and dispositions of the assets
  of the Company;
- Provide reasonable assurance that transactions are recorded as necessary to
  permit preparation of financial statements in accordance with generally
  accepted accounting principles, and that receipts and expenditures are being
  made only in accordance with authorizations of management and the director;
  and
- Provide reasonable assurance regarding prevention or timely detection of
  unauthorized acquisition, use or disposition of assets that could have a
  material effect on the financial statements.

As required by Rule 13a-15 and 15d-15 under the Securities and
Exchange Act of 1934, Management assessed the effectiveness of the Companys
internal control over financial reporting as of December 31, 2009. Based on this
assessment, the Company's management has concluded that the Company maintained
effective internal control over financial reporting as of December 31, 2009, the
end of the period covered by this quarterly report.

This quarterly report does not include an attestation report of
the company's registered public accounting firm regarding internal control over
financial reporting. Management's report was not subject to attestation by the
company's registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission ("SEC") that permit the Company to provide
only management's report in this quarterly report.

Changes in Internal Control over Financial Reporting.Management has evaluated whether any changes in our internal control over
financial reporting that occurred during our last fiscal quarter have materially
effected, or reasonably likely to materially effect our internal control over
financial reporting. Based on the evaluation we conducted, management has
concluded that during the fiscal quarter ending December 31, 2009, there were no
changes in the Company's internal control over financial reporting during the
period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Company's internal control over financial
reporting.

---

A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues, if any, within a company have been detected. The Company's
disclosure controls and procedures are designed to provide reasonable assurance
of achieving their objectives, and the Principal Executive Officer and the
Principal Financial Officer have concluded that these controls and procedures
are effective at the "reasonable assurance" level.

PART II  OTHER INFORMATION



|Item 1. | **Legal
  Proceedings.**
|------- | ------------------------

We are not currently a party to any legal proceedings.

|Item 1A. | **Risk
Factors.**
|-------- | -----------------

Not applicable.

|Item 2. | **Unregistered Sales of Equity Securities
      and Use of Proceeds.**
|------- | ----------------------------------------------------------------------

None.

|Item 3. | **Defaults Upon Senior
      Securities.**
|------- | ------------------------------------------

None.

|Item 4. | **Submission of Matters to a Vote of
      Security Holders.**
|------- | --------------------------------------------------------------

No matters have been submitted to our security holders for a
  vote, through the solicitation of proxies or otherwise, during the quarterly
period ended December 31, 2009.

|Item 5. | **Other
  Information.**
|------- | ------------------------

None.



|Item 6. | **Exhibits.**
|------- | -------------

|31.1 | Certification of Principal Executive Officer pursuant to
  Section 302 of the Sarbanes-Oxley Act of 2002.    
|---- | -------------------------------------------------------------------------------------------------------------
|     |                                                                                                              
|31.2 | Certification of Principal Financial Officer pursuant to
      Section 302 of the Sarbanes-Oxley Act of 2002.
|     |                                                                                                              
|32.1 | Certification of Principal Executive Officer pursuant to
      Section 906 of the Sarbanes-Oxley Act of 2002.
|     |                                                                                                              
|32.2 | Certification of Principal Financial Officer pursuant to
      Section 906 of the Sarbanes-Oxley Act of 2002.

---

SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|                              |  | PURE PHARMACEUTICALS CORPORATION                         
|----------------------------- |  | ---------------------------------------------------------
|                              |  | (Registrant)                                             
|                              |  |                                                          
|                              |  |                                                          
|Date: February 12,
      2010 |  | By:
      /s/ Roger Gordon                               
|                              |  | Roger Gordon                                             
|                              |  | President, Principal Executive Officer and
      Director
|                              |  |                                                          
|                              |  |                                                          
|                              |  |                                                          
|Date: February 12,
      2010 |  | By:
      /s/ Charlie Lee                                
|                              |  | Charlie Lee                                              
|                              |  | Secretary and Principal Accounting Officer               

---